1 / 45

Pharmacological Aspects of Myopia

Myopia: Strategies for the 21st Century. Pharmacological Aspects of Myopia. Christine Wildsoet University of California Berkeley. Christine Wildsoet, OD, PhD • UC Berkeley Optometry • vision.berkeley.edu/VSP/CW • wildsoet@spectacle.berkeley.edu .

elia
Download Presentation

Pharmacological Aspects of Myopia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Myopia: Strategies for the 21st Century Pharmacological Aspects of Myopia Christine Wildsoet University of California Berkeley Christine Wildsoet, OD, PhD • UC Berkeley Optometry • vision.berkeley.edu/VSP/CW • wildsoet@spectacle.berkeley.edu

  2. Pharmacological intervention - not a very new idea Bedrossian atropine study (1966) • Underlying assumption • Excessive near work involved • Excessive accommodation implicated

  3. Bedrossian (1966) Study • 1% atropine nightly • age 7-13 yr • progressing myopes • refractions only Swap overtime Incr. progression

  4. Pharmacological intervention - options for treatment • Determining factors • Is myopia genetic &/or nonvisual? • Are visual factors involved? Scleral target Animal models Retinal (& higher level)target

  5. Animal models Lesson from Bedrossian: Measure eye length + refractive errors

  6. Drug options - Results fromexperimental studies & clinical trials • Main focus of studies • Dopaminergic agonists • Antimuscarinic drugs • Recent focus of attention • Nicotinic drugs • NO analogs • Retinoic acid • Glucagonergic analogs • GABA analogs • Others studied • bFGF • TNF-b • VIP • Melatonin • Enkephalins Retina - target for many studies!

  7. Issues to consider in animal-based drug studies • Form deprivation myopia paradigm mostly commonly used • Form deprivation myopia & lens-induced myopia may involve different mechanisms • Intravitreal injection most common route of adminstration Relevance of studies to human myopia?

  8. The retina as a drug targetMany transmitters, many drug options! Amacrine cells & their transmitters of particular interest

  9. DA analogs -First to be tested with animal models Low retinal DA • Rationale • DA regulates retinal coupling • DA influences retinal spatial processing High retinal DA

  10. Dopamine analogs - Summary of observed effects • dopamine agonists inhibit myopia development • chick • monkey Key work in this area Stone, Laties & Tigges (chicks & monkeys) Schaeffel lab (chicks) Stell lab (chicks) Wildsoet & Schmid (chicks) Seko (chicks)

  11. DA analogs - The earliest study?Chicks & form deprivation myopia Stone et al. Proc Nat Acad Sci (1989)

  12. Apomorphine & chicks Effects on lens-induced myopia -15 D lenses: worn from 8 days for 4 days Schmid & Wildsoet ARVO (1998)

  13. Apomorphine, FDM & monkeys Form deprived (FD) 5-8 monthswith opaque contact lenses Tigges et al. Invest Ophthalmol Vis Sci (1991)

  14. Apomorphine, RPE & scleral growth in chick Retinal pigment epitheium cultured with scleral chondrocytes +/- apomorphine Seko et al. Cell, Biochemistry & Function (1997)

  15. Dopaminergic effects - Some apparent inconsistencies • dopamine turnover decreases in FDM & LIM BUT • dopamine antagonists can also inhibit eye growth • agonists+antagonists enhance myopia • 6-OHDA inhibits FDM, not LIM • reserpine inhibits both FDM & LIM FDM: form deprivation myopia LIM: lens induced myopia

  16. Antimuscarinic drugs - Summary of observed effects • Antimuscarinic drugs inhibit myopia development • chicks • tree shrews • monkeys • humans Key work in this area Stone, Laties & Tigges (chicks/monkeys) Schaeffel lab (chicks) McBrien lab (chicks & tree shrews) Wildsoet & Schmid (chicks) Wallman lab (chicks) Shih (chicks) SERI (chicks)

  17. Antimuscarinic drugs - Important insight from chick Ach receptors on chick ciliary musclesare nicotinic! Ciliary muscle is not the site of action Accommodation not the target!

  18. Antimuscarinic drugs -the earliest chick study Increasing dose Lid suture for 2 weeks + daily SC injections Atropine (Atr, nonselective) Pirenzepine (Pir; M1) Methoctramine (Met; M2) 4-DAMP (DAMP, M3) Stone et al. Exp Eye Res (1991)

  19. M4-selective antimuscarinic drugs also work! Chicks were form deprived & treated with himbacine, a M4 selective agent Cottriall et al. NeuroReport (2001)

  20. Atropine & lens-induced myopia in chicks Intravitreal injections 25 ug atropine every other day; measured after 7 days Wildsoet, McBrien & Clark ARVO (1994)

  21. Antimuscarinic drugs - They also work in mammals & primates Monkey Tigges et al. Optom Vis Sci (1999)

  22. DA analogs + antimuscarinic drugsCan they be combined to improve efficacy? Chicks: treated from day 8 - day 12 Schmid & WildsoetProc Aust Neurosci Soc (2000)

  23. DA - Ach analog interactions Another perspective from DFP Chicks form deprived & injected i.vit. with 2 ug DFP every other day +/-DA antagonists Cottriall & McBrien NS Arch Pharm (2001)

  24. Retinally-active drugs -Other possibilities • Nicotinic analogs • NOS inhibitors

  25. Nicotinic analogs & myopia in chicks Chicks form-deprived CHL: chlorisondamine MEC: mecamylamine MLA: methyllcaconitine DHBE: dihyrdo-b-erythroidine Stone et al. Invest Ophthalmol Vis Sci (2001)

  26. Nitric oxide analogs - Inhibition via a retinal pathway? Chicks treated with 180 mM l-NAME & -16 D lens (significant effects observed at doses>60 mM) l-NAME inhibitsoscillatorypotentials Fujikado et al. Ophthalmic Res (2001)

  27. Retinally-active drugs “work” They tell us about mechanisms BUTHow safe is the retina as a site of action for myopia control?

  28. The neglected targets - IOP, scleral growth & ocular rhythms • Targeted drugs • timolol • latanoprost • melatonin

  29. IOP, timolol & myopia control in chicks -15 D lens Diffusers Schmid et al. Exp Eye Res (2001) IOP decrease 8-10%, FDM; 13-14% LIM

  30. Latanoprost & myopia inhibitionin chicks - Effect via IOP (or PGs)? Form-deprived for 1 week BID X2, separated by 3 days BID Jin & Stjernschantz Acta Ophthalmol Scand (2000)

  31. The sclera - An alternative site of action for myopia control drugs? Curtin, 1985

  32. b-xyloside study Inhibition PG synthesis in chicks Rada et al.Exp Eye Res (2002)

  33. The sclera - An alternative site of action for antimuscarinic drugs? • Evidence • ECMA lesions • cell culture

  34. ECMA lesions, atropine & myopia in chicks Chicks treated with 25 nmol ECMA, +/- form deprivation & 40 ug atropine daily for 6 days Fischer et al. Brain Res (1998)

  35. Scleral cell culture & myopia in chicks Thymidine incorporation Sulfate incorporation by chondrocytes Atr: atropine Pir: Pirenzepine DAMP: 4-DAMP Lind et al. Invest Ophthal Vis Sci (1998)

  36. So what about humans?

  37. Timolol - Not effective for human myopia control! 0.25% timolol, BID Jensen Acta Ophthalmologica (1991)

  38. Atropine & human myopiaRecent findings are promising! Refraction changes over 18 months - 0.25% atropine + multifocals cf. multifocal & single vision spectacles Shih et al.Acta Ophthalmol Scand (2001)

  39. Pirenzepine & human myopiaRumor has it that results from on-going trials are very promising!

  40. But is it just that simple?

  41. Myopia control treatment - There are significant unresolved issues • Required treatment is very long term • chronically applied topical drugs causeocular surface disease &/or allergies • chronically applied drugs cause tolerance • Target group is young • a retinal target site carries inherent risks • Questions to consider • Is there a better (safer) site - Yes,sclera? • Are there alternative routes of administration? • Are there other nonclassical drug options?

  42. Is oral administration a possibility?Pirenzepine works in chicks Flitcroft, Troilo & Wildsoet 8th International Myopia Meeting (2000)

  43. Other drug options - Retinoic acid & effects on eye growth Chick scleral punches assayed in culture Mertz & Wallman Exp Eye Res (2001)

  44. Fos-labelling Control 2hr treated Antisense drugs & eye growth control in chicks AODN: antisense oligodeoxynucleotide McGuire & Stell (2000)

  45. Drugs for myopia control The best way forward?

More Related